Brown Advisory Inc. increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP – Get a rating) by 23.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund held 17,634 shares of the specialty pharmaceutical company after acquiring an additional 3,333 shares during the period. Brown Advisory Inc. owned 0.10% of ANI Pharmaceuticals worth $496,000 at the end of the most recent reporting period.
Other hedge funds have also recently increased or reduced their holdings in the company. Thompson Siegel & Walmsley LLC increased its position in ANI Pharmaceuticals shares by 51.7% during the first quarter. Thompson Siegel & Walmsley LLC now owns 424,087 shares of the specialty pharmaceutical company worth $11,921,000 after purchasing an additional 144,533 shares during the period. Dimensional Fund Advisors LP increased its stake in ANI Pharmaceuticals by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 389,304 shares of the specialty pharmaceutical company worth $17,940,000 after acquiring 11,088 additional shares in the last quarter. Emerald Advisers LLC increased its stake in ANI Pharmaceuticals by 326.8% in the 1st quarter. Emerald Advisers LLC now owns 354,045 shares of the specialty pharmaceutical company valued at $9,952,000 after acquiring an additional 271,101 shares during the period. Rubric Capital Management LP acquired a new position in ANI Pharmaceuticals in Q4 valued at approximately $14,172,000. Finally, Emerald Mutual Fund Advisers Trust increased its position in ANI Pharmaceuticals shares by 234.7% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 299,493 shares of the specialty pharmaceutical company worth $8,419,000 after buying an additional 210,002 shares last quarter. 59.66% of the shares are currently held by hedge funds and other institutional investors.
Analysts set new price targets
Several equity research analysts have recently weighed in on ANIP shares. StockNews.com moved shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Raymond James raised his price target on ANI Pharmaceuticals from $47.00 to $48.00 and gave the company an “outperform” rating in a Tuesday, August 9 research note. Two equity research analysts gave the stock a hold rating and two gave the company a buy rating. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.00.
ANI Pharmaceuticals stock up 5.9%
Shares of NASDAQ ANIP opened at $37.47 on Friday. The company has a 50-day moving average of $30.50 and a two-hundred-day moving average of $31.73. ANI Pharmaceuticals, Inc. has a 1-year low of $22.31 and a 1-year high of $60.23. The company has a quick ratio of 2.74, a current ratio of 3.35 and a leverage ratio of 0.92.
ANI Pharmaceuticals (NASDAQ: ANIP – Get a rating) last announced its quarterly results on Monday, August 8. The specialty pharma company reported EPS of $0.13 for the quarter, missing the consensus estimate of $0.22 per ($0.09). ANI Pharmaceuticals recorded a negative net margin of 25.32% and a positive return on equity of 3.68%. In the same quarter a year earlier, the company earned $0.49 per share. Research analysts expect ANI Pharmaceuticals, Inc. to post EPS of 0.71 for the current fiscal year.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures and markets branded and generic prescription pharmaceutical products in the United States and Canada. It focuses on the production of controlled substances, oncology products, hormones and steroids, injectables and other formulations. The company manufactures solid oral dose products; semi-solids, liquids and topicals; and potency products, as well as the development and contract manufacturing of pharmaceutical products for other companies.
Get news and reviews for ANI Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ANI Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.